Advertisement

Current Neurology and Neuroscience Reports

, Volume 12, Issue 3, pp 261–266 | Cite as

Schizophrenia Genetics: Putting All the Pieces Together

  • Simon L. Girard
  • Patrick A. Dion
  • Guy A. RouleauEmail author
Genetics (V Bonifati, Section Editor)

Abstract

Schizophrenia is a major mental disorder characterized by a deep disruption of the thinking process and of emotional response. For many decades, genetics studies have yielded little success in identifying genetic factors responsible for the disease. However, with the recent breakthroughs in genome analysis technologies, the field of the genetics of schizophrenia has progressed a lot in the last years. Both common and rare variants have been successfully associated with the disease and a particular emphasis has been made on rare copy number variations. Recently, a new paradigm linking de novo mutations to the genetic mechanism of schizophrenia has been unravelled. The aim of this review is to discuss the most important genetic studies made in the field to give a general perspective of where to go in the future.

Keywords

Schizophrenia Genetics Genomics GWAS Genome-wide association study Sequencing Next-generation sequencing De novo CNV Copy number variation Linkage studies Psychiatric disorder Mental disorder 

Notes

Disclosure

Conflicts of interest: S.L. Girard: none; P.A. Dion: none; G.A. Rouleau: none.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Tienari P. Schizophrenia in Finnish male twins. In: Lader MH, editor. Studies of schizophrenia. 1975. pp. 29–35.Google Scholar
  3. 3.
    Fischer M, Harvald B, Hauge M. A Danish twin study of schizophrenia. Br J Psychiatry. 1969;115(526):981–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Kendler KS, Robinette CD. Schizophrenia in the National Academy of Sciences-National Research Council Twin Registry: a 16-year update. Am J Psychiatry. 1983;140(12):1551–63.PubMedGoogle Scholar
  5. 5.
    Onstad S, Skre I, Torgersen S, Kringlen E. Twin concordance for DSM-III-R schizophrenia. Acta Psychiatr Scand. 1991;83(5):395–401.PubMedCrossRefGoogle Scholar
  6. 6.
    Cannon TD, Kaprio J, Lönnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry. 1998;55(1):67–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 1999;56(2):162–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Riley B. Linkage studies of schizophrenia. Neurotox Res. 2004;6(1):17–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Pulver AE, Karayiorgou M, Wolyniec PS, et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: part 1. Am J Med Genet. 1994;54(1):36–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Petryshen TL, Middleton FA, Kirby A, et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry. 2005;10(4):366–74. 328.PubMedCrossRefGoogle Scholar
  13. 13.
    Seshadri S, Kamiya A, Yokota Y, et al. Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc Natl Acad Sci U S A. 2010;107(12):5622–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Bray NJ, Preece A, Williams NM, et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet. 2005;14(14):1947–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Blackwood DH, Fordyce A, Walker MT, et al. Schizophrenia and affective disorders–cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet. 2001;69(2):428–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000;9(9):1415–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Brandon NJ, Millar JK, Korth C, et al. Understanding the role of DISC1 in psychiatric disease and during normal development. J Neurosci. 2009;29(41):12768–75.PubMedCrossRefGoogle Scholar
  18. 18.
    Betcheva ET, Mushiroda T, Takahashi A, et al. Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population. J Hum Genet. 2009;54(2):98–107.PubMedCrossRefGoogle Scholar
  19. 19.
    Shifman S, Johannesson M, Bronstein M, et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 2008;4(2):e28.PubMedCrossRefGoogle Scholar
  20. 20.
    Kirov G, Zaharieva I, Georgieva L, et al. A genome-wide association study in 574 schizophrenia trios using DNA pooling. Mol Psychiatry. 2009;14(8):796–803.PubMedCrossRefGoogle Scholar
  21. 21.
    Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008;13(6):570–84.PubMedCrossRefGoogle Scholar
  22. 22.
    O’Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008;40(9):1053–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Steinberg S, Mors O, Borglum AD, et al. Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry. 2010;16(1):59–66.Google Scholar
  24. 24.
    Riley B, Thiselton D, Maher BS, et al. Replication of association between schizophrenia and ZNF804A in the Irish Case–control Study of Schizophrenia sample. Mol Psychiatry. 2010;15(1):29–37.PubMedCrossRefGoogle Scholar
  25. 25.
    Hill MJ, Jeffries AR, Dobson RJB, Price J, Bray NJ. Knockdown of the psychosis susceptibility gene ZNF804A alters expression of genes involved in cell adhesion. Hum Mol Genet. 2011;21(5):1018–24.Google Scholar
  26. 26.
    • Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744–7. This is one of the first GWAS that identified the MHC as an associated region.PubMedGoogle Scholar
  27. 27.
    • Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748–52. This is one of the first GWAS that identified the MHC as an associated region.PubMedGoogle Scholar
  28. 28.
    Handel AE, Ramagopalan SV. The potential role of major histocompatibility complex class I in schizophrenia. Biol Psychiatry. 2010;68(7):e29–30. author reply e31.PubMedCrossRefGoogle Scholar
  29. 29.
    Shi Y, Li Z, Xu Q, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet. 2011;43(12):1224–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Yue W-H, Wang H-F, Sun L-D, et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet. 2011;43(12):1228–31.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43(10):969–76. This is the largest GWAS made on a SCZ cohort. It identifies MIR137 as an associated locus.PubMedCrossRefGoogle Scholar
  32. 32.
    Balaguer F, Link A, Lozano JJ, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 2010;70(16):6609–18.PubMedCrossRefGoogle Scholar
  33. 33.
    Liu M, Lang N, Qiu M, et al. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer. 2011;128(6):1269–79.PubMedCrossRefGoogle Scholar
  34. 34.
    Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008;6:14.PubMedCrossRefGoogle Scholar
  35. 35.
    Tarantino C, Paolella G, Cozzuto L, et al. miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells. FASEB J. 2010;24(9):3255–63.PubMedCrossRefGoogle Scholar
  36. 36.
    • Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320(5875):539–43. This is one of the most important genome-wide CNV studies made in the field of SCZ.PubMedCrossRefGoogle Scholar
  37. 37.
    Xu B, Roos JL, Levy S, et al. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet. 2008;40(7):880–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Anon. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455(7210):237–41.CrossRefGoogle Scholar
  39. 39.
    • Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455(7210):232–6. This is one of the most important genome-wide CNV study made in the field of SCZ.PubMedCrossRefGoogle Scholar
  40. 40.
    Mulle JG, Dodd AF, McGrath JA, et al. Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum Genet. 2010;87(2):229–36.PubMedCrossRefGoogle Scholar
  41. 41.
    McCarthy SE, Makarov V, Kirov G, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet. 2009;41(11):1223–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Ingason A, Rujescu D, Cichon S, et al. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry. 2009;16(1):17–25.Google Scholar
  43. 43.
    •• Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010;464(7289):713–20. This study made by the WTCCC shows that the common CNVs are unlikely to contribute significantly to disease as they are already tagged by the SNPs.PubMedCrossRefGoogle Scholar
  44. 44.
    Malhotra D, McCarthy S, Michaelson JJ, et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011;72(6):951–63.PubMedCrossRefGoogle Scholar
  45. 45.
    • Gauthier J, Champagne N, Lafreniere RG, et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A. 2010;107(17):7863–8. This is the first study to report a de novo mutation in a gene and to associate this gene with the disease.PubMedCrossRefGoogle Scholar
  46. 46.
    Tarabeux J, Champagne N, Brustein E, et al. De novo truncating mutation in Kinesin 17 associated with schizophrenia. Biol Psychiatry. 2010;68(7):649–56.PubMedCrossRefGoogle Scholar
  47. 47.
    Gauthier J, Siddiqui TJ, Huashan P, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet. 2011;130(4):563–73.Google Scholar
  48. 48.
    • Awadalla P, Gauthier J, Myers RA, et al. Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet. 2010;87(3):316–24. This study has shown that the de novo mutation rate is higher than expected in SCZ.PubMedCrossRefGoogle Scholar
  49. 49.
    •• Girard SL, Gauthier J, Noreau A, et al. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet. 2011;43(9):860–3. This study has shown a higher than expected rate of de novo mutation as well as identified a strong enrichment in de novo truncating mutations.PubMedCrossRefGoogle Scholar
  50. 50.
    •• Xu B, Roos JL, Dexheimer P, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 2011;43(9):864–8. This study has shown a higher than expected rate of de novo mutation as well as identified a strong enrichment in nonsynonymous mutations.PubMedCrossRefGoogle Scholar
  51. 51.
    O’Roak BJ, Deriziotis P, Lee C, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011;43(6):585–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Vissers LE, de Ligt J, Gilissen C, et al. A de novo paradigm for mental retardation. Nat Genet. 2010;42(12):1109–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Simon L. Girard
    • 1
  • Patrick A. Dion
    • 1
    • 2
  • Guy A. Rouleau
    • 1
    • 3
    • 4
    Email author
  1. 1.Centre of Excellence in Neuromics of Université de MontréalCentre Hospitalier de l’Université de Montréal Research CenterMontréalCanada
  2. 2.Department of Pathology and Cellular BiologyUniversité de MontréalMontréalCanada
  3. 3.Centre of Excellence in Neuromics of Université de MontréalCentre Hospitalier Universitaire Sainte-Justine Research CenterMontréalCanada
  4. 4.Faculty of Medicine, Department of MedicineUniversité de MontréalMontréalCanada

Personalised recommendations